|
Extranodal NK/T-cell lymphoma, nasal type
|
317 (51.0)
|
217/100
|
43.0 (10–86)
|
|
Angioimmunoblastic T-cell lymphoma
|
118 (19.0)
|
82/36
|
63.0 (36–87)
|
|
Peripheral T-cell lymphoma, not otherwise specified
|
81 (13.0)
|
58/23
|
49.0 (25–81)
|
|
Anaplastic large-cell lymphoma, ALK-positive
|
31 (5.0)
|
19/12
|
21.0 (4–69)
|
|
Anaplastic large-cell lymphoma, ALK-negative
|
15 (2.4)
|
10/5
|
45.0 (8–76)
|
|
Primary cutaneous, anaplastic large-cell lymphoma
| | |
48.0 (24–81)
|
|
13 (2.1)
|
4/9
|
7.5 (2–13)
|
|
Hydroa vacciniforme-like LPD
|
12 (1.9)
|
8/4
| |
|
Subcutaneous panniculitis-like T-cell lymphoma
|
12 (1.9)
|
5/7
|
36.0 (17–55)
|
|
Monomorphic epitheliotropic intestinal T-cell lymphoma
|
9 (1.4)
|
6/3
|
50.0 (38–82)
|
|
Hepatosplenic T-cell lymphoma
|
5 (0.8)
|
4/1
|
37.0 (29–44)
|
|
Primary cutaneous CD4-positive small/medium T-cell LPD
|
3 (0.4)
|
3/0
|
40.0 (22–60)
|
|
Primary cutaneous γδ T-cell lymphoma
|
2 (0.3)
|
1/1
|
19.0 (2–36)
|
|
Mycosis fungoides
|
2 (0.3)
|
1/1
|
29.0 (18–40)
|
|
Aggressive NK-cell leukemia
|
2 (0.3)
|
2/0
|
27.0 (22–32)
|
|
Total
|
622
|
420/202
|
47.5 (2–87)
|
